Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...

Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

Telehealth stock Hims & Hers ( HIMS) spiked more than 24% in trading Thursday, days after its Super Bowl ad promoting cheaper GLP-1 weight-loss drugs sparked controversy.

When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Pfizer clinches the top spot in the competitive 2025 Super Bowl ad race, promising groundbreaking visibility during the big ...

We recently published a list of 10 Firms Post Double-Digit Gains on Thursday. In this article, we are going to take a look at ...

Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

Viewers of the Super Bowl may have seen an ad from one of the largest compounders in the United States, Hims & Hers, ...

Novo Nordisk (NYSE: NVO) stock is in a funk. Monday's decline probably owes to rival GLP-1 company Hims & Hers Health running ...